04153nam 2200709Ia 450 991045938450332120200520144314.01-282-63948-X97866126394871-4008-3511-910.1515/9781400835119(CKB)2670000000035226(EBL)540270(OCoLC)655342133(SSID)ssj0000427070(PQKBManifestationID)11965268(PQKBTitleCode)TC0000427070(PQKBWorkID)10390665(PQKB)10069665(MiAaPQ)EBC540270(MdBmJHUP)muse36704(DE-B1597)446670(OCoLC)979745514(DE-B1597)9781400835119(Au-PeEL)EBL540270(CaPaEBR)ebr10394772(CaONFJC)MIL263948(EXLCZ)99267000000003522620091106d2010 uy 0engur|n|---|||||txtccrReputation and power organizational image and pharmaceutical regulation at the FDA[electronic resource] /Daniel CarpenterCourse BookPrinceton Princeton University Pressc20101 online resource (825 p.)Princeton studies in American politicsDescription based upon print version of record.0-691-14179-7 0-691-14180-0 Includes bibliographical references and index.Cover; CONTENTS; LIST OF ILLUSTRATIONS; LIST OF TABLES; ACKNOWLEDGMENTS; LIST OF ABBREVIATIONS AND ACRONYMS; INTRODUCTION: The Gatekeeper; CHAPTER ONE: Reputation and Regulatory Power; PART ONE: ORGANIZATIONAL EMPOWERMENT AND CHALLENGE; CHAPTER TWO: Reputation and Gatekeeping Authority: The Federal Food, Drug and Cosmetic Act of 1938 and Its Aftermath; CHAPTER THREE: The Ambiguous Emergence of American Pharmaceutical Regulation, 1944-1961; CHAPTER FOUR: Reputation and Power Crystallized: Thalidomide, Frances Kelsey, and Phased Experiment, 1961-1966CHAPTER FIVE: Reputation and Power Institutionalized: Scientific Networks, Congressional Hearings, and Judicial Affirmation, 1963-1986CHAPTER SIX: Reputation and Power Contested: Emboldened Audiences in Cancer and AIDS, 1977-1992; PART TWO: PHARMACEUTICAL REGULATION AND ITS AUDIENCES; CHAPTER SEVEN: Reputation and the Organizational Politics of New Drug Review; CHAPTER EIGHT: The Governance of Research and Development: Gatekeeping Power, Conceptual Guidance, and Regulation by Satellite; CHAPTER NINE: The Other Side of the Gate: Reputation, Power, and Post-Market RegulationCHAPTER TEN: The Détente of Firm and RegulatorCHAPTER ELEVEN: American Pharmaceutical Regulation in International Context: Audiences, Comparisons, and Dependencies; CHAPTER TWELVE: Conclusion: A Reputation in Relief; PRIMARY SOURCES AND ARCHIVAL COLLECTIONS; INDEX The U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints. Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to rePrinceton studies in American politics.Pharmaceutical policyUnited StatesDrugsResearchUnited StatesElectronic books.Pharmaceutical policyDrugsResearch362.17/82Carpenter Daniel P.1967-878941MiAaPQMiAaPQMiAaPQBOOK9910459384503321Reputation and power organizational image and pharmaceutical regulation at the FDA1962629UNINA